---
title: Clinical Outcomes and Efficacy of Left Ventricular Assist Device for Korean Patients With Cardiogenic Shock
nct_id: NCT02985008
overall_status: UNKNOWN
sponsor: Jeong Hoon Yang
study_type: OBSERVATIONAL
primary_condition: Shock, Cardiogenic
countries: South Korea
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02985008.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02985008"
ct_last_update_post_date: 2016-12-07
last_seen_at: "2026-05-12T07:34:43.955Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Clinical Outcomes and Efficacy of Left Ventricular Assist Device for Korean Patients With Cardiogenic Shock

**Official Title:** SMart Angioplasty Research Team: A Multi-center, Open, REtrospective and Prospective Observational Study to Investigate Clinical oUtcomes and Efficacy of Left Ventricular Assist Device for Korean Patients With Cardiogenic Shock : RESCUE

**NCT ID:** [NCT02985008](https://clinicaltrials.gov/study/NCT02985008)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 1000
- **Lead Sponsor:** Jeong Hoon Yang
- **Conditions:** Shock, Cardiogenic
- **Start Date:** 2016-04
- **Completion Date:** 2019-12
- **CT.gov Last Update:** 2016-12-07

## Brief Summary

Retrospectively and prospectively enrolled patients with cardiogenic shock in domestic manifolds and investigated the current state of treatment and clinical features of cardiogenic shock in Koreans and identified the factors that could improve the prognosis and the use of IABP and ECMO And to investigate its therapeutic effect.

## Detailed Description

1. The selection / exclusion criteria for persons with cardiogenic shock should be verified by medical records from January 1, 2014 before the approval date of each institution's clinical trial screening committee.
2. If a cardiogenic shock to the selection criteria is found in the emergency room, general ward, or intensive care unit of the participating institutions, enroll in this study and fill in the information according to the e-CRF.
3. After 1, 6 and 12 months, visit the hospital for examination and procedures. The person in charge of the examination or the delegate of the examiner may follow the person by telephone or an outpatient visit.

## Eligibility

- **Minimum age:** 19 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. 19 years old or older
2. ① Systolic blood pressure is less than 90mmHg for more than 30 minutes despite the fluid therapy, or Use of pressure boosting agents is necessary.

   ② Peripheral hypopnea (cold skin, urine less than 30 cc per hour, impaired consciousness, lactate ≥2.0 mmol / l) or a person with pulmonary edema.
3. Causes of cardiogenic shock include acute myocardial infarction (including in coronary intervention), cardiomyopathy, myocarditis, pulmonary embolism, refractory ventricular tachycardia, shock during coronary intervention.
4. Those voluntarily consenting to the medical records and the data necessary for the study during the entire study period.

Exclusion Criteria:

1. Other causes except for cardiogenic shock (low blood pressure, septic, obstructive shock)
2. Shock with cardiac arrest outside the hospital
3. People with allergic reactions to anticoagulants such as heparin.
4. Those who refused active treatment.
```

## Primary Outcomes

- **In hospital death** _(time frame: for 1 year)_

## Secondary Outcomes

- **Death in 28days** _(time frame: 28days)_
- **Death in 1 year** _(time frame: 1 year)_
- **Death, myocardial infarction, stroke, re-admission due to heart failure during follow-up.** _(time frame: 1 year)_
- **Number of days of intensive care unit Number of days of intensive care unit** _(time frame: 1 year)_
- **hospitalization days** _(time frame: 1 year)_
- **Lactate 24 hour clearance** _(time frame: 1 year)_
- **Successful removal of left ventricular assist device (IABP, ECMO)** _(time frame: 1 year)_

## Locations (1)

- Samsung Medical Center, Seoul, Seoul, South Korea — _RECRUITING_

## Recent Field Changes (last 30 days)

- `outcomes.primary` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.samsung medical center|seoul|seoul|south korea` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02985008.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02985008*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*